Trial Profile
Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Oct 2020
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Rosuvastatin
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms ANTARES
- 25 Sep 2020 Status changed from recruiting to discontinued.
- 07 May 2018 Status changed from not yet recruiting to recruiting.
- 03 Apr 2018 New trial record